Related by context. All words. (Click for frequent words.) 72 adenocarcinomas 70 carcinoma 67 lung cancers 67 squamous cell carcinoma 67 prostate cancers 67 bladder cancers 66 colorectal cancers 66 pancreatic cancers 66 malignancy 66 adenoma 66 gastric cancers 66 lobular carcinoma 66 tumors 65 papillary 65 carcinomas 65 hepatocellular carcinoma HCC 65 squamous cell 65 lymph node metastases 65 pancreatic adenocarcinoma 65 neoplasm 65 mucinous 65 endometrial cancers 64 lung tumors 64 gastric cancer 64 breast cancers 64 cell carcinoma 64 basal cell carcinoma BCC 64 invasive ductal carcinoma 64 squamous cell carcinoma SCC 64 melanoma 64 mesotheliomas 64 invasive ductal 63 cancers 63 PCa 63 oropharyngeal cancer 63 squamous cell carcinomas 63 GISTs 63 rectal cancers 63 breast tumors 63 gliomas 63 cell carcinomas 63 colorectal cancer 63 NSCLC 63 HNSCC 63 colorectal carcinoma 63 Adenocarcinoma 63 serous ovarian cancer 63 metastatic disease 63 breast carcinomas 63 hepatocellular carcinoma 63 advanced adenomas 63 colorectal tumors 62 neoplasms 62 renal cell carcinoma 62 squamous cell cancers 62 atypical hyperplasia 62 Wilms tumor 62 paraganglioma 62 renal cell carcinomas 62 astrocytoma 62 micrometastases 62 cutaneous melanoma 62 adenomas 62 soft tissue sarcomas 61 malignancies 61 ovarian cancers 61 urothelial carcinoma 61 Papillary 61 lung adenocarcinoma 61 colon cancers 61 situ LCIS 61 gastrointestinal stromal tumor 61 HER2 positive 61 metastatic prostate cancer 61 lung metastases 61 liver metastases 61 carcinoid 61 basal cell 61 distant metastases 61 PNET 61 endometrioid 61 anaplastic 61 metastases 61 uveal melanoma 61 intestinal metaplasia 61 neoplasia 61 distant metastasis 61 renal tumors 61 metastatic 61 axillary lymph nodes 61 melanomas 61 medullary thyroid cancer 61 carcinoid tumors 61 metastatic cancer 60 Metastatic 60 pleomorphic 60 EGFR mutation 60 situ DCIS 60 Carcinoma 60 MALT lymphoma 60 neuroendocrine tumors 60 basal cell carcinomas 60 hormone receptor positive 60 glioma 60 esophageal cancers 60 invasive carcinoma 60 thymoma 60 pleural mesothelioma 60 premalignant lesions 60 lung carcinomas 60 malignant pleural mesothelioma 60 gastric adenocarcinoma 60 Barrett esophagus 60 ductal carcinoma 60 seminoma 60 meningiomas 60 squamous cell cancer 60 metastatic tumors 60 ccRCC 60 breast carcinoma 60 nonmelanoma skin cancers 60 sarcomatoid 60 Renal cell carcinoma 60 lymph node involvement 60 neoplasias 59 osteosarcomas 59 sarcoma 59 esophageal adenocarcinoma 59 neoplastic lesions 59 cholangiocarcinoma 59 colorectal polyps 59 nasopharyngeal carcinoma 59 prostate cancer CaP 59 meningioma 59 malignant lymphoma 59 basal cell carcinoma 59 basal cell cancers 59 nonsmall cell lung cancer 59 brain metastases 59 colorectal cancer CRC 59 metastatic renal cell carcinoma 59 lymphomas 59 ovarian tumors 59 DCIS 59 cell lung cancer 59 CaP 59 advanced adenoma 59 MGUS 59 node metastases 59 epithelioid 59 rs# [002] 59 colorectal gastric 59 grade gliomas 59 glioblastoma 59 hyperplastic 59 leiomyosarcoma 59 squamous 59 metastatic lung cancer 59 thyroid cancers 59 bowel cancers 59 hamartomas 59 testicular cancers 59 poorer prognosis 59 ADPKD 59 frequently benign tumor 59 neuroblastomas 59 GBM tumors 58 estrogen receptor positive 58 esophageal squamous cell carcinoma 58 oesophageal adenocarcinoma 58 prostate tumor 58 prostate carcinoma 58 transitional cell carcinoma 58 premalignant 58 Cholangiocarcinoma 58 ductal 58 HER2 positive cancers 58 malignant prostate 58 Basal cell carcinoma 58 malignant melanoma 58 papillary RCC 58 pulmonary metastases 58 hepatocellular carcinomas 58 cell lymphoma ALCL 58 angiosarcoma 58 oesophageal cancer 58 histologic subtype 58 Glioblastomas 58 precursor lesions 58 lung cancer 58 paragangliomas 58 medulloblastoma 58 neoplastic 58 estrogen receptor negative 58 lobular cancer 58 esophagogastric junction 58 synovial sarcoma 58 T1a 58 KRAS wild 58 ovarian carcinoma 58 DLBCL 58 metastatic lesions 58 ovarian lung 58 seminomas 58 colorectal adenoma 58 papillary carcinoma 58 peritoneal carcinomatosis 57 grade cervical intraepithelial 57 glioblastomas 57 CIN3 57 Non Hodgkin lymphoma 57 malignant neoplasm 57 histologically 57 cisplatin resistant 57 nonmetastatic 57 pheochromocytomas 57 Glioblastoma 57 sporadic ALS 57 follicular lymphoma 57 squamous carcinoma 57 unresectable 57 lobular breast cancer 57 radical nephrectomy 57 colorectal polyp 57 liposarcoma 57 tumor recurrence 57 lung nodules 57 epithelial tumors 57 malignant tumors 57 nodular melanoma 57 astrocytomas 57 HER2 positive breast cancer 57 resectable 57 Basal cell 57 squamous cell lung cancer 57 lobular carcinomas 57 gastrointestinal cancers 57 ALCL 57 contralateral breast 57 neuroendocrine carcinoma 57 castration resistant prostate cancer 57 leiomyomas 57 colorectal adenocarcinoma 57 epithelial ovarian cancer 57 epithelial ovarian 57 ductal breast cancer 57 pheochromocytoma 57 hepatocellular cancer 57 Gastric cancer 57 HGPIN 57 invasive lobular 57 supratentorial 57 atypia 57 proximal colon 57 malignant lesions 57 colorectal liver metastases 57 ductal lobular 57 pancreatic tumor 57 medically inoperable 57 ependymoma 57 carcinoid tumor 56 lung metastasis 56 basal cell cancer 56 malignant growths 56 liver metastasis 56 papillary thyroid carcinoma 56 thromboembolic events 56 lymphocytosis 56 hepatic metastases 56 metastatic colorectal 56 metastatic bladder 56 leukaemias 56 neoadjuvant therapy 56 NAFLD 56 papillary renal cell carcinoma 56 metachronous 56 ductal adenocarcinoma 56 PCNSL 56 ductal cancer 56 peritoneal cancer 56 stage IIIB 56 lobular 56 BRAF mutations 56 hamartoma 56 chondrosarcoma 56 malignant melanomas 56 endometrial cancer 56 basal cell nevus syndrome 56 HER2 + 56 lymphocytic leukemia 56 lymph node metastasis 56 progesterone receptor negative 56 prostate adenocarcinoma 56 mycosis fungoides 56 nonmelanoma skin cancer 56 invasive lobular carcinoma 56 small lymphocytic lymphoma 56 polypoid 56 glioma rarer 56 HER2 negative 56 rectal cancer 56 bone metastasis 56 BRCA mutations 56 dysplasia 56 adenomatous polyps 56 colorectal neoplasms 56 gastrointestinal stromal tumors 56 EGFR mutations 56 biliary tract cancer 56 carcinoids 56 laryngeal cancer 56 wedge resection 56 Squamous cell carcinoma 56 relapsing remitting 56 pre cancerous lesion 56 histological subtype 56 renal carcinoma 56 choriocarcinoma 56 hepatoma 56 GIST 56 Glioblastoma multiforme GBM 56 preoperative chemotherapy 56 pancreatic NET 56 biochemical recurrence 56 Glioma 56 GBMs 56 differentiated thyroid 56 cell lymphomas 56 ependymomas 56 cervical carcinoma 56 adenoid cystic carcinoma 56 Squamous 56 HER2 positive tumors 56 atherosclerotic lesions 56 B Cell Lymphoma 55 operable breast cancer 55 dysplastic 55 Follicular lymphoma 55 metastatic RCC 55 invasive breast cancer 55 Uterine fibroids 55 neurofibromas 55 NMIBC 55 colorectal 55 glioblastoma multiforme GBM 55 recurrent NSCLC 55 geographic atrophy 55 contralateral breast cancer 55 PSADT 55 Squamous cell 55 ductal carcinomas 55 urothelium 55 nodal metastasis 55 thyroid nodules 55 hormone receptor negative 55 colorectal adenomas 55 papillary thyroid cancer 55 imatinib resistant 55 lymphoma 55 histologically confirmed 55 gastric cardia 55 medulloblastomas 55 CIN2 55 metastatic colorectal cancer 55 BRAF mutation 55 pancreatic tumors 55 CIN2 + 55 malignant fibrous histiocytoma 55 locoregional recurrence 55 xenograft tumors 55 benign tumors 55 malignant gliomas 55 urothelial cancer 55 lung colorectal 55 curable cancers 55 IDH1 mutation 55 Glioblastoma Multiforme GBM 55 estrogen receptor ER 55 ovarian cancer 55 rhabdomyosarcoma 55 gastric carcinoma 55 adenomatous 55 SPINK1 55 teratoma 55 melanoma tumors 55 thyrotoxicosis 55 Metastatic breast cancer 55 infarcts 55 Helicobacter pylori infection 55 oropharyngeal squamous cell carcinoma 55 subependymal giant cell 55 stage IIIb IV 55 metastatic melanomas 55 hyperplastic polyps 55 metastatic colon cancer 55 benign growths 55 BRCA1 mutations 55 prostate cancer PCa 55 neuroendocrine cancers 55 tumor shrinkage 55 thyroid carcinomas 55 grade dysplasia 55 APOL1 55 IV melanoma 55 metastatic melanoma 55 histologic subtypes 55 neuroblastoma tumors 55 epithelial cancers 55 advanced hepatocellular carcinoma 55 GSTP1 55 colon tumors 55 Tumours 55 nodal metastases 55 alveolar rhabdomyosarcoma 55 carotid stenosis 55 p# mutations 54 Carcinoid tumors 54 breast pancreatic 54 lymphoproliferative disorders 54 lymphovascular invasion 54 Tumors 54 microbleeds 54 malignant polyps 54 basal cell skin 54 metastasis 54 Anaplastic 54 molecular subtypes 54 NF1 54 pituitary adenomas 54 metastatic gastric 54 leukemia AML 54 GIST tumors 54 liver cancer 54 lymphadenopathy 54 chemoradiation 54 brain tumors 54 primitive neuroectodermal tumor 54 tumor 54 squamous cells 54 Barrett mucosa 54 total thyroidectomy 54 schwannomas 54 periodontitis 54 subtype 54 BRCA2 mutations 54 lymphadenectomy 54 esophageal tumors 54 Gliomas 54 ovarian pancreatic 54 superficial bladder cancer 54 proliferative diabetic retinopathy 54 colonic polyps 54 papillomas 54 breast cancer subtypes 54 metastatic cancers 54 solar keratosis 54 adjuvant radiotherapy 54 radical prostatectomy RP 54 Acute lymphoblastic leukemia 54 malignant cancerous 54 antigen PSA 54 non Hodgkin lymphomas 54 Hurthle cell 54 hyperplasia 54 Glioblastoma Multiforme 54 histologies 54 FGFR2 54 Kaposi sarcoma 54 bladder cancer 54 Synovial sarcoma 54 metastatic breast cancer 54 Wilms tumors 54 colorectum 54 hypopharynx 54 TP# mutations 54 nodular 54 bladder tumors 54 solid tumors 54 renal pelvis 54 mutated KRAS 54 Testicular cancer 54 cardia 54 lung pancreatic 54 colorectal neoplasia 54 HER2 amplification 54 osteosarcoma 54 nasopharyngeal cancer 54 KRAS mutation 54 adrenocortical cancer 54 grade glioma 54 colon cancer 54 skin cancers 54 urothelial 54 prostate tumors 54 pancreatic carcinoma 54 pancreatic cancer 54 SCCHN 54 leukemia CLL 54 colorectal lung 54 esophageal gastric 54 PAOD 54 PGDH 54 SLNB 54 atypical ductal hyperplasia 54 commonly mutated genes 54 Metastases 54 salpingo oophorectomy 54 hypermethylation 54 skeletal metastases 54 situ CIS 54 cystic lesions 54 stage IIIA 54 esophagectomy 54 oophorectomy 54 BRCA2 mutation carriers 54 oligodendrogliomas 54 HNPCC 54 microsatellite instability 54 ERBB2 54 intraepithelial neoplasia 54 extracranial 54 squamous cell skin 54 polyposis 53 Glioblastoma multiforme 53 rs# [003] 53 squamous histology 53 lung adenocarcinomas 53 glioblastoma tumors 53 tunica vaginalis 53 invasive ductal carcinomas 53 myelodysplastic syndrome MDS 53 BRCA mutation carriers 53 BRCA deficient 53 HBeAg negative 53 testicular tumors 53 Osteosarcoma 53 metastatic malignant melanoma 53 HPV# 53 neoadjuvant chemotherapy 53 pneumonectomy 53 pancreatic colorectal 53 benign breast 53 malignant mesothelioma 53 follicular lymphoma FL 53 retroperitoneal 53 immunohistochemical staining 53 Adjuvant chemotherapy 53 EGFR mutation positive 53 colorectal pancreatic 53 metastatic carcinoma 53 malignant neoplasms 53 invasive carcinomas 53 non squamous NSCLC 53 bile duct cancers 53 gastroesophageal junction 53 postoperative pathology 53 precancerous lesions 53 sarcomas 53 extracapsular extension 53 seminal vesicle invasion 53 activating mutations 53 vulvar intraepithelial neoplasia 53 Lung cancer 53 leukoplakia 53 glioblastoma GBM 53 completely resected 53 resected 53 radiosensitive 53 endometrial carcinoma 53 Brain metastases 53 bleomycin 53 recurrent glioblastoma multiforme 53 pancreatic endocrine 53 nephrectomy 53 micronuclei 53 diffuse gastric 53 malignant nodules 53 transurethral resection 53 unresectable tumors 53 axillary lymph node dissection 53 cytokeratin 53 lymphocytic 53 neovascular AMD 53 cytogenetic responses 53 germline mutations 53 T2DM 53 advanced NSCLC 53 leiomyoma 53 Sezary syndrome 53 locoregional 53 tumors GIST 53 cervical lymph nodes 53 familial pancreatic cancer 53 hyperparathyroidism 53 B7 H3 53 myelofibrosis polycythemia vera 53 Adenomas 53 familial ALS 53 ApoE4 53 adjuvant therapy 53 non squamous 53 metastatic basal cell 53 EGFRvIII 53 Ductal carcinoma 53 Merkel cell carcinoma 53 adrenalectomy 53 sulfasalazine 53 GNAQ 53 Polyps 53 untreated celiac disease 53 T1c 53 cytoreduction 53 CIN3 + 53 recurrent colorectal cancer 53 endometrial hyperplasia 53 pancreatic ductal adenocarcinoma 53 tumor xenograft models 53 pT3 53 occult metastases 53 primary biliary cirrhosis 53 Squamous cell carcinomas 53 chemoradiotherapy 53 anti angiogenic therapy 53 malignant brain 53 follicular thyroid cancer 53 metastatic adenocarcinoma 53 epithelia 53 HER2 overexpression 53 Melanomas 53 postmenopausal breast cancer 53 lobules 53 BRAF V#E 53 diverticulum 53 cancerous enlargement 53 osteochondroma 53 essential thrombocythemia 53 nonmelanoma 53 promoter methylation 53 chronic prostatitis 53 luminal cells 53 serum creatinine levels 53 prostate cancer CRPC 53 cervical lesions 53 pre cancerous lesions 53 tumor histology 53 Colon polyps 53 TCF#L# gene 52 intraductal 52 estrogen receptor progesterone receptor 52 Nodules 52 pancreatic neuroendocrine 52 neoadjuvant treatment 52 HER2 receptor 52 metaplasia 52 fallopian tube carcinoma 52 pCR 52 heterotopic ossification 52 distal colon cancer 52 pathologic diagnosis 52 heavily pretreated 52 RASSF1A 52 localized renal 52 clinicopathological 52 malignant 52 gastrointestinal stromal tumor GIST 52 MSH2 52 nonalcoholic steatohepatitis NASH 52 lipomas 52 lymph node removal 52 neuroblastoma cells 52 carcinomatosis 52 hypercalcemia 52 sorafenib 52 noncarriers 52 serrated polyps 52 precancers 52 neurofibroma 52 cirrhotic 52 lymphoblastic leukemia 52 BCG refractory 52 Hashimoto thyroiditis 52 lung cancer NSCLC 52 colorectal liver 52 histopathologic 52 frontotemporal dementia 52 intestinal polyps 52 curative resection 52 melanoma skin 52 TEAEs 52 cystic 52 Bladder cancer 52 gallstone disease 52 oesophageal 52 CYT# potent vascular disrupting 52 lymphatic tissue 52 Hepatocellular Carcinoma HCC 52 pancreatic 52 H. pylori 52 mammary cancers 52 oligodendroglioma 52 K ras mutations 52 acute myeloid 52 PTHrP 52 pelvic lymphadenectomy 52 ASCUS 52 eosinophilic esophagitis 52 disease NAFLD 52 BRCA1 mutation carriers 52 biliary strictures 52 cytoreductive surgery 52 Burkitt lymphoma 52 CLL 52 homozygosity 52 uterine cancers 52 Cell Lung Cancer 52 prognostic factor 52 Radical prostatectomy 52 infiltrating ductal carcinoma 52 invasive bladder 52 overexpress 52 axillary lymph node 52 fibroadenomas 52 taxane therapy 52 cutaneous squamous cell carcinoma 52 systolic dysfunction 52 WT1 52 recurrent glioblastoma 52 oesophageal squamous cell carcinoma 52 Malignant melanoma 52 prostate pancreatic 52 histologic 52 endobronchial 52 distal colon 52 metastatic pancreatic 52 bronchioloalveolar carcinoma 52 bladder ovarian 52 cancerous lesions 52 Colorectal 52 sentinel lymph node biopsy 52 p# mutation 52 #.#ng/ml 52 JMML 52 FTLD 52 TT genotype 52 MYCN amplification 52 androgen deprivation 52 Rectal cancer 52 bilateral oophorectomy 52 cystectomy 52 FLT3 52 biliary tract 52 invasive ductal breast cancer 52 leukemia ALL 52 trans retinoic acid 52 indolent lymphomas 52 non resectable 52 pilocytic astrocytomas 52 hepatectomy 52 daunorubicin 52 FDG uptake 52 ALK mutations 52 thyroglobulin 52 lymph nodes 52 interstitial pneumonia 52 Metastatic melanoma 52 varices 52 Ewing sarcoma 52 penetrance 52 Neuroendocrine tumors 52 colectomy 52 chronic lymphocytic leukemia CLL 52 benign polyps 52 Malignant mesothelioma 52 histopathologic examination 52 oral squamous cell 52 choroidal neovascularization CNV 52 pT2 52 dasatinib 52 TIMP 52 parenchyma 52 dysplastic nevi 52 adriamycin 52 superficial basal cell carcinoma 52 HER2 positive metastatic breast 52 cholelithiasis 52 ovarian carcinomas 52 H pylori 52 Chronic lymphocytic leukemia 52 cancerous breast 52 gadolinium enhanced 52 Fas ligand 52 carcinoma HNSCC 52 polyp recurrence 52 polypoid lesions 52 Malignant Melanoma 52 macroalbuminuria 52 hepatorenal syndrome 52 Barrett esophagus BE 52 pilocytic astrocytoma 52 ocular melanoma 52 mRCC 52 TNF blocker therapy 52 thyroid carcinoma 52 immunoreactivity 52 extranodal 52 invasive ductal cancer 52 cell lymphoma DLBCL 52 lymphoid 52 monogenic 52 Gleevec resistant 52 breast endometrial 52 nonresponders 52 pegylated liposomal doxorubicin 52 LHRH receptor positive 52 atherosclerotic disease 52 graft dysfunction 52 clinicopathologic 52 Sarcomas 52 invasive cervical cancer 52 TCF#L# 52 chlorambucil 51 acute aortic dissection 51 Cancers 51 chromosome #q# [002] 51 polyps 51 Stent thrombosis 51 EGFR gene 51 sentinel node 51 precancerous condition 51 overexpressed 51 Epithelial ovarian cancer 51 pericardial effusion 51 Toxicities 51 basal cells 51 mCRC patients 51 cytologically 51 gastrectomy 51 Sjögren syndrome 51 SSc 51 embryonal rhabdomyosarcoma 51 uterine tumors 51 parathyroid carcinoma 51 prophylactic cranial irradiation 51 mammary tumors 51 submucosa 51 alveolar soft 51 polycythemia vera 51 BRAF gene 51 Pancreatic cancer 51 caveolin 1 51 Hazard Ratio 51 precancerous polyp 51 lymphoid malignancies 51 anthracyclines 51 leukemias lymphomas 51 idiopathic PAH 51 benign neoplasms 51 paroxysmal AF 51 lymph node 51 colorectal carcinomas 51 pre cancerous growths 51 localized prostate cancer 51 nondiabetic patients 51 chromophobe 51 bronchogenic carcinoma 51 BRAF V#E mutation 51 nevi 51 histological subtypes 51 chronic GVHD 51 fibrosis 51 diabetes mellitus DM 51 advanced neoplasia 51 Irinotecan 51 adenomatous polyp 51 EGFR 51 ABCB1 51 IV NSCLC 51 primitive neuroectodermal tumors 51 acute leukemias 51 HER2 expression 51 mTOR inhibitors 51 fibrous dysplasia 51 cytologically confirmed 51 colon pancreas 51 uterine ovarian 51 metastatic relapsed 51 upregulated 51 refractory multiple myeloma 51 sarcosine 51 osteoblastic 51 malignant pheochromocytoma 51 relapsing remitting MS 51 Inflammatory breast cancer 51 elevated LDH 51 nasopharynx 51 pharyngeal cancer 51 mutated KRAS gene 51 hypermethylated 51 lipid abnormalities 51 esophageal carcinoma 51 desmoplastic 51 GSTT1 51 proteinuria 51 LCIS 51 metastatic pancreatic cancer 51 castrate resistant 51 radiographic findings 51 hematologic toxicity 51 glioblastoma multiforme 51 ER alpha 51 asymptomatic 51 microscopic hematuria 51 resected pancreatic cancer 51 androgen independent 51 anterior uveitis 51 benign moles 51 axillary dissection 51 molecular abnormalities 51 lesions 51 Endometrial cancer 51 sentinel nodes 51 fallopian tube cancers 51 parathyroid 51 EoE 51 atrophic gastritis 51 HLA B# 51 MLL AF9 51 IV malignant melanoma 51 subclinical hypothyroidism 51 keloids 51 prostate cancer 51 gefitinib 51 indolent NHL 51 penile cancers 51 fibroadenoma 51 axillary 51 Rhabdomyosarcoma 51 breast lesions 51 adjuvant radiation 51 cerebral infarction 51 vimentin 51 prostate ovarian 51 metastatic ovarian cancer 51 prostate specific 51 venous thrombosis 51 rs# [004] 51 systemic scleroderma 51 aminotransferases 51 chronic myeloid 51 squamous cell histology 51 CLL SLL 51 cervical intraepithelial neoplasia 51 KRAS mutations 51 FGFR1 51 xenografts 51 axillary node dissection 51 MLH1 51 ErbB2 51 oropharynx 51 GSTM1 51 hemangiomas 51 metastatic breast 51 biliary tract cancers 51 subclinical hyperthyroidism 51 ovarian breast 51 hypoplasia 51 lacunar 51 BRCA1 BRCA2 51 asymptomatic carotid stenosis 51 lichen planus 51 chronic periodontitis 51 unresectable stage 51 Myelofibrosis 51 spontaneously regress 51 Adjuvant therapy 51 hepatic cirrhosis 51 SUVmax 51 Epstein Barr virus EBV 51 Colorectal cancers 51 iNOS 51 incidentalomas 51 clinically detectable 51 metastatic malignant 51 acute myelogenous leukemia AML 51 liver resection 51 pancreatic neuroendocrine tumors 51 1 diabetes T1D 51 allogeneic stem cell 51 homozygotes 51 prostate colon 51 serum PSA 51 pre malignant lesions 51 5FU 51 MTHFR 51 PARP inhibition 51 osteopetrosis 51 chemoresistance 51 colon esophageal 51 Wegener granulomatosis